Shots:
- Variant Bio has expanded its multi-year research collaboration & license agreement with BI to discover and validate novel cardiovascular disease targets using its Inference platform, building on their existing kidney disease collaboration
- As per the terms of the expanded agreement, Variant Bio will receive an additional upfront payment & over $250M in potential license & milestone payments
- The AI-powered Inference platform performs end-to-end genomic analysis using proprietary genomic, deep-phenotyping, & multi-omic data from studies across diverse global populations
Ref: PRnewswire | Image: Variant Bio & BI | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
